Labcorp Announces Winning Bid for Select Assets of Invitae
- Labcorp's acquisition of Invitae's assets is expected to boost its revenue by $275-$300 million annually, with a focus on oncology and rare diseases testing.
- The purchase price for the transaction is $239 million, showcasing Labcorp's strategic investment in expanding its specialty testing capabilities.
- The transaction, subject to court approval on May 6, 2024, is anticipated to close in the third quarter of 2024 pending regulatory approvals, positioning Labcorp for growth in specialized testing areas.
- None.
Looking at Labcorp's strategic acquisition of Invitae assets, we're examining a decision that is expected to bolster their specialty testing capabilities, particularly in oncology and rare diseases. The anticipated annual revenue increase of
The purchase price of
The requirement for court approval is a critical step in this transaction, particularly as Invitae's assets are part of a bankruptcy auction. The legal proceedings are likely to be scrutinized for any objections that could arise and potentially delay the transaction beyond the third quarter of 2024. Investors will need to pay attention to the hearing scheduled for May 6, 2024, as any issues here could impact the timeline for revenue generation from the acquired assets.
Another legal aspect that merits attention is the role of regulatory bodies. Given the nature of the healthcare industry, any acquisitions involving medical services or technologies typically go through a rigorous examination process. Labcorp's legal counsel, Hogan Lovells and Kilpatrick Townsend, will need to navigate these hurdles efficiently to mitigate delays and facilitate a smooth transition.
When assessing the market implications of Labcorp's move, it's important to consider the growing demand for specialty testing services. Oncology and rare disease testing represent areas with high growth potential due to advancements in personalized medicine and genetic diagnostics. Labcorp could significantly increase its market share in these niches with the acquisition of Invitae's assets.
Furthermore, strategic acquisitions can create synergies, such as expanding client bases and leveraging existing infrastructure. However, integration of new assets poses risks, including operational disruptions and cultural mismatches. How Labcorp manages these risks will be a determinant of their ability to capitalize on the anticipated revenue growth and translate it into shareholder value.
Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases
Transaction requires court approval, with confirmation expected on May 6, 2024
Upon completion, Labcorp expects this transaction would generate approximately
The transaction is anticipated to close in third quarter of 2024, subject to customary closing conditions for a transaction of this type, including applicable regulatory approvals.
Through this transaction, Labcorp would acquire assets being auctioned through a voluntary bankruptcy protection process.
Hogan Lovells and Kilpatrick Townsend are serving as Labcorp's legal counsel.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for
About Invitae
Invitae (OTC: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. To learn more, visit invitae.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to the terms of the transaction, its approval by the bankruptcy court, and the benefits to the company, patients, and physicians if the transaction is completed.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the risk that the transaction may not be completed in a timely manner or at all; (ii) expected timing to closing; (iii) the failure to satisfy closing conditions, including the receipt of certain regulatory approvals; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the transaction agreements; (v) potential difficulties with employee retention and employee relations; (vi) competitive actions and other unforeseen changes and general uncertainties in the marketplace; (vii) changes in government regulations; (viii) customer purchasing decisions, including changes in payer regulations or policies, and increased competition; (ix) other adverse actions of governmental and third-party payers; (x) changes in testing guidelines or recommendations; (xi) the impact of global geopolitical events; (xii) failure to maintain or develop customer relationships; (xiii) failure in information technology, systems or data security; (xiv) personnel costs; and (xv) inflation. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC, including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".
# # #
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-announces-winning-bid-for-select-assets-of-invitae-302126850.html
SOURCE Laboratory Corporation of America Holdings
FAQ
What assets did Labcorp win the bid for from Invitae?
When is the court expected to confirm the approval for the transaction?
What is the expected annual revenue generation from the transaction for Labcorp?
When is the transaction anticipated to close?
Who are serving as Labcorp's legal counsel for this transaction?
